表紙
市場調査レポート

鎮静状態 - パイプライン分析

Sedation - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 253662
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
鎮静状態 - パイプライン分析 Sedation - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 58 Pages
概要

鎮静状態とは、興奮や動揺した状態を抑えた状態です。症侯は、ゆっくり話し、舌がもつれることもあり、集中できない、フラフラする、呼吸や心拍数が落ち、血圧が低くなるなどです。 鎮静状態にするためにはバルビツール酸誘導体やベンゾジアゼピン誘導体を使います。

当レポートでは、鎮静薬の開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • AstraZeneca PLC
  • AcelRx Pharmaceuticals, Inc.
  • Paion AG
  • 丸石製薬
  • NanoMedex Pharmaceuticals, Inc.
  • Advicenne Pharma

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • propofol
  • ADV-6209
  • remimazolam
  • (sufentanil + triazolam)
  • MR-04A3
  • LASSBio-786
  • LASSBio-785
  • propofol Microemulsion
  • clonidine hydrochloride

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7573IDB

Summary

Global Markets Direct's, 'Sedation - Pipeline Review, H1 2016', provides an overview of the Sedation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sedation
  • The report reviews pipeline therapeutics for Sedation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sedation therapeutics and enlists all their major and minor projects
  • The report assesses Sedation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sedation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sedation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sedation Overview
  • Therapeutics Development
    • Pipeline Products for Sedation - Overview
  • Sedation - Therapeutics under Development by Companies
  • Sedation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Sedation - Products under Development by Companies
  • Sedation - Companies Involved in Therapeutics Development
    • Advicenne Pharma
    • AstraZeneca Plc
    • Drawbridge Pharmaceuticals Pty Ltd
    • Jiangsu Nhwa Pharmaceutical Corporation Ltd.
    • NanoMedex Pharmaceuticals, Inc.
    • Paion AG
    • The Medicines Company
    • Therakind Limited
  • Sedation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABP-700 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADV-6209 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alphaxalone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clonidine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EL-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • propofol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • propofol microemulsion - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • remimazolam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize GABA-A for Sedation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sedation - Recent Pipeline Updates
  • Sedation - Dormant Projects
  • Sedation - Discontinued Products
  • Sedation - Product Development Milestones
    • Featured News & Press Releases
      • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
      • Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings
      • Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan
      • Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
      • Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
      • May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward
      • Mar 31, 2015: PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy
      • Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
      • Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
      • Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sedation, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Sedation - Pipeline by Advicenne Pharma, H1 2016
  • Sedation - Pipeline by AstraZeneca Plc, H1 2016
  • Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2016
  • Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H1 2016
  • Sedation - Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2016
  • Sedation - Pipeline by Paion AG, H1 2016
  • Sedation - Pipeline by The Medicines Company, H1 2016
  • Sedation - Pipeline by Therakind Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Sedation Therapeutics - Recent Pipeline Updates, H1 2016
  • Sedation - Dormant Projects, H1 2016
  • Sedation - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Sedation, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top